Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 3, 2001, Pages 347-354

  Talley, N J ^a   Lauritsen, K ^b   Tunturi Hihnala, H ^c   Lind, T ^d   Moum, B ^e   Bang, C ^f   Schulz, T ^g   Omland, T M ^f   Delle, M ^h   Junghard, O ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d Karnsjukhuset   (Sweden)

^e Östfold Central Hospital   (Norway)

^f Specialistgruppen ^*  (Norway)

^g Aust Agder Central Hospital   (Norway)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT SATISFACTION; PROTON PUMPS; STEREOISOMERISM; TREATMENT OUTCOME;

EID: 0035114856     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00943.x     Document Type: Article

References (19)

1. Treatment of gastro-esophageal reflux disease in adults
2. Pharmacological management of gastro-esophageal reflux disease
3. Gastro-esophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
4. Trends in the management of gastro-esophageal reflux disease
5. Long-term management of gastro-esophageal reflux disease
6. Three-year follow up of patients with gastro-esophageal reflux disease
7. An evidence-based appraisal of reflux disease management - The Genval Workshop Report
8. Phamacokinetics (PK) and Dose-response Relationship of Esomeprazole (E)
9. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease
10. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis: A randomized controlled trial
11. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis in GERD patients
12. On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial
13. Gastro-oesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings
14. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-esophageal reflux disease in general practice
15. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease
16. Helicobacter pylori and the efficacy of omeprazole therapy for gastro-esophageal reflux disease
17. Gastric Helicobacter pylori infection accelerates healing of reflux oesophagitis during treatment with the proton pump inhibitor pantoprazole
18. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials
19. Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease: Determination of criteria and relation to endoscopy